Dianthus Therapeutics (NASDAQ:DNTH) Shares Down 2.5% - Here's Why

Shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Get Free Report) were down 2.5% on Thursday . The company traded as low as $22.05 and last traded at $22.32. Approximately 6,067 shares changed hands during mid-day trading, a decline of 97% from the average daily volume of 204,738 shares. The stock had previously closed at $22.90.

Analyst Ratings Changes

A number of analysts recently commented on the stock. Raymond James upgraded shares of Dianthus Therapeutics to a "moderate buy" rating in a research report on Thursday, December 12th. HC Wainwright reaffirmed a "buy" rating and set a $40.00 price target on shares of Dianthus Therapeutics in a research report on Monday, November 11th. TD Cowen started coverage on Dianthus Therapeutics in a research report on Friday, December 20th. They issued a "buy" rating for the company. Finally, Oppenheimer raised their price objective on shares of Dianthus Therapeutics from $48.00 to $52.00 and gave the stock an "outperform" rating in a report on Monday, November 11th. Eight research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat, Dianthus Therapeutics has an average rating of "Buy" and a consensus target price of $46.43.

Dianthus Therapeutics Stock Up 0.4 %

The company's fifty day moving average is $25.35 and its 200 day moving average is $26.66. The firm has a market cap of $680.73 million, a price-to-earnings ratio of -9.20 and a beta of 1.75.

Dianthus Therapeutics (NASDAQ:DNTH - Get Free Report) last announced its quarterly earnings data on Thursday, November 7th. The company reported ($0.74) earnings per share for the quarter, missing the consensus estimate of ($0.59) by ($0.15). Dianthus Therapeutics had a negative net margin of 1,250.32% and a negative return on equity of 21.68%. The company had revenue of $2.17 million during the quarter, compared to the consensus estimate of $1.07 million. On average, equities research analysts forecast that Dianthus Therapeutics, Inc. will post -2.61 EPS for the current fiscal year.

Institutional Investors Weigh In On Dianthus Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the stock. Bank of New York Mellon Corp increased its holdings in Dianthus Therapeutics by 860.5% during the second quarter. Bank of New York Mellon Corp now owns 80,935 shares of the company's stock worth $2,095,000 after buying an additional 72,509 shares during the last quarter. Rhumbline Advisers acquired a new position in shares of Dianthus Therapeutics during the 2nd quarter worth about $832,000. American Century Companies Inc. lifted its stake in Dianthus Therapeutics by 38.6% in the 2nd quarter. American Century Companies Inc. now owns 30,432 shares of the company's stock valued at $788,000 after purchasing an additional 8,473 shares during the last quarter. WINTON GROUP Ltd acquired a new position in shares of Dianthus Therapeutics during the 2nd quarter worth approximately $265,000. Finally, Great Point Partners LLC grew its holdings in Dianthus Therapeutics by 21.3% in the 2nd quarter. Great Point Partners LLC now owns 757,929 shares of the company's stock valued at $19,615,000 after buying an additional 132,929 shares in the last quarter. Institutional investors own 47.53% of the company's stock.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.